# A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-head-to-head-comparison-of-ixekizumab-vs-guselkumab-in-patients-with-moderate/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Andrew Blauvelt,C. Leonardi,Boni E. Elewski,Jeffrey Crowley,Lyn Guenther,Melinda Gooderham,Richard G. Langley,Ronald Vender,Andreas Pinter,C.E.M. Griffiths,Yayoi Tada,Hany Elmaraghy,Renata Gontijo Lima,Gaia Gallo,L. Renda,Russel Burge,S.Y. Park,Baojin Zhu,Kim Papp,the IXORA‐R Study Group |
| Citations | 120 |
| DOI | 10.1111/bjd.19509 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjd.19509 |
| OpenAlex ID | https://openalex.org/W4249995199 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Yayoi Tada](https://scholariq.org/researchers/yayoi-tada/)

## Paper journal

- [British Journal of Dermatology](https://scholariq.org/journals/british-journal-of-dermatology/)

## Paper primary topic

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Paper topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Cytokine Signaling Pathways and Interactions](https://scholariq.org/topics/cytokine-signaling-pathways-and-interactions/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.